SUPERNUS PHARMACEUTICALS INC's ticker is SUPN and the CUSIP is 868459108. A total of 233 filers reported holding SUPERNUS PHARMACEUTICALS INC in Q4 2021. The put-call ratio across all filers is 1.01 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $5,789,953 | -57.6% | 159,811 | -58.3% | 0.81% | -56.7% |
| Q4 2022 | $13,670,884 | +5.4% | 383,260 | +0.0% | 1.87% | +7.7% |
| Q3 2022 | $12,971,000 | +7.6% | 383,180 | -8.0% | 1.73% | +6.0% |
| Q2 2022 | $12,050,000 | +64.8% | 416,650 | +84.2% | 1.64% | +99.3% |
| Q1 2022 | $7,311,000 | -17.7% | 226,216 | -25.7% | 0.82% | -36.1% |
| Q4 2021 | $8,878,000 | +144.5% | 304,455 | +401.8% | 1.28% | -7.5% |
| Q2 2018 | $3,631,000 | +91.3% | 60,670 | +46.4% | 1.39% | +51.5% |
| Q1 2018 | $1,898,000 | +83.0% | 41,445 | +59.9% | 0.92% | +41.3% |
| Q3 2017 | $1,037,000 | -64.9% | 25,920 | -62.2% | 0.65% | -67.0% |
| Q2 2017 | $2,958,000 | +481.1% | 68,635 | +322.2% | 1.97% | +170.5% |
| Q1 2017 | $509,000 | -54.0% | 16,255 | -62.9% | 0.73% | -45.5% |
| Q4 2016 | $1,106,000 | +353.3% | 43,790 | +343.9% | 1.34% | +332.4% |
| Q3 2016 | $244,000 | -67.8% | 9,865 | -73.5% | 0.31% | -72.9% |
| Q2 2016 | $757,000 | – | 37,170 | – | 1.14% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 426,500 | $11,754,340 | 3.96% |
| ASHFORD CAPITAL MANAGEMENT INC | 916,747 | $25,274,715 | 3.72% |
| ARMISTICE CAPITAL, LLC | 5,092,000 | $140,386,440 | 2.15% |
| S&T BANK/PA | 215,578 | $5,943 | 1.15% |
| Aristotle Capital Boston, LLC | 1,187,981 | $32,752,634 | 1.06% |
| RICE HALL JAMES & ASSOCIATES, LLC | 544,468 | $15,010,983 | 0.95% |
| Tributary Capital Management, LLC | 352,429 | $9,716,468 | 0.92% |
| Bridge City Capital, LLC | 65,297 | $1,800,238 | 0.91% |
| Integral Health Asset Management, LLC | 220,000 | $6,065,400 | 0.84% |
| Retirement Planning Co of New England, Inc. | 51,608 | $1,422,833 | 0.79% |